Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding

Published: Jan 12, 2018


Jan. 12, 2018 12:00 UTC

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has decided not to grant the Company’s Post Grant Review (PGR) petition challenging the validity of U.S. Patent No. 9,662,335 (referred to as the ’335 patent) assigned to Incyte Pharmaceuticals.

“We are disappointed that the PTAB has denied our petition on the ’335 patent. This decision does not prohibit us from challenging the validity of the patent at a later time in federal court, and we will continue with our plans to develop CTP-543 for alopecia areata. We don’t expect any disruption to our clinical timelines,” said Roger Tung, President and CEO of Concert Pharmaceuticals. “We remain committed to developing the first FDA-approved treatment for alopecia areata; however, we are reassessing whether to expand CTP-543 into additional indications.”

In July 2017, Concert filed a PGR petition challenging the validity of Incyte’s ’335 patent covering deuterated ruxolitinib analogs. Documents relating to the PGR can be accessed online at: http://www.concertpharma.com/technology-overview/intellectual-property/.

About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs. The Company’s approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert has a broad pipeline of innovative medicines targeting autoimmune and inflammatory diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the strength of Concert's intellectual property, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

 

Contacts

Investors
Concert Pharmaceuticals, Inc.
Justine Koenigsberg, 781-674-5284
ir@concertpharma.com
or
Media
The Yates Network
Kathryn Morris, 914-204-6412
kathryn@theyatesnetwork.com

 
 

Source: Concert Pharmaceuticals, Inc.

Back to news